Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Med Discovery SA

This article was originally published in Start Up

Executive Summary

Switzerland's Med Discovery was founded on the discovery of a prostate cancer target, human kallikrein 2, a key protease associated with prostate biology that is thought to contribute to cancer progression and development. The start-up's lead protease inhibitor targets hK2 and is based on the natural serine protease inhibitor ACT, which the company believes will avoid the selectivity and toxicities of other protease inhibitors. Med Discovery is developing the candidate for prostate cancer, but it believes it also has potential for treating skin disorders and for immunological treatment of cancer.
Advertisement

Related Content

Colby Pharmaceutical Co.
Start-Up Previews (03/2009)
Bellicum Pharmaceuticals Inc.
Treating Late-Stage Prostate Cancer
AndroBioSys Inc.
Start-Up Previews (03/2009)
Treating Late-Stage Prostate Cancer
Prostate Cancer Market: $2 Billion and Growing

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC091757

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel